<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412735</url>
  </required_header>
  <id_info>
    <org_study_id>MSB-DR003</org_study_id>
    <nct_id>NCT02412735</nct_id>
  </id_info>
  <brief_title>Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain</brief_title>
  <acronym>MSB-DR003</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3
      study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or
      combined with hyaluronic acid (HA) in subjects with chronic low back pain (&gt; 6 months)
      associated with moderate radiographic degenerative changes of a disc
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success (composite responder analysis of low back pain Visual Analogue Scale (VAS) score, Oswestry Disability Index (ODI) score and no post-treatment interventions)</measure>
    <time_frame>24 Months</time_frame>
    <description>• To determine Overall Treatment Success of rexlemestrocel-L alone or rexlemestrocel-L+HA through 24 months based on a composite responder analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness (Pain Responder analysis)</measure>
    <time_frame>24 months</time_frame>
    <description>• To evaluate the effectiveness of rexlemestrocel-L alone or rexlemestrocel-L+HA in reducing chronic low back pain by performing a Pain Responder analysis through 24 months post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness (Functional Responder analysis)</measure>
    <time_frame>24 months</time_frame>
    <description>• To evaluate the effectiveness of rexlemestrocel-L alone or rexlemestrocel-L+HA in improving function by performing a Functional Responder analysis through 24 months post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness (Treatment Success at 24 months)</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the Treatment Success at 24 months of rexlemestrocel-L alone or rexlemestrocel-L+HA based upon a composite responder analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness (Minimal Pain Responder at 24 months)</measure>
    <time_frame>24 months</time_frame>
    <description>Minimal Pain Responder at 24 Months: Measured as subjects meeting low back pain VAS score threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness (Time to first intervention)</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the effectiveness of rexlemestrocel-L alone or rexlemestrocel-L+HA on reducing the time to additional interventions at the treated level over 24 months post-treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <arm_group>
    <arm_group_label>rexlemestrocel-L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rexlemestrocel-L alone&quot;: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rexlemestrocel-L + HA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rexlemestrocel-L + HA&quot;: 2.0mL 6 million rexlemestrocel-L cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline control: 2.0 mL saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rexlemestrocel-L</intervention_name>
    <description>rexlemestrocel-L alone&quot;: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells - Intervention will be injected into the painful intervertebral disc</description>
    <arm_group_label>rexlemestrocel-L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rexlemestrocel-L + HA</intervention_name>
    <description>rexlemestrocel-L + HA&quot;: 2.0mL 6 million rexlemestrocel-L cells with 1% HA - Intervention will be injected into the painful intervertebral disc</description>
    <arm_group_label>rexlemestrocel-L + HA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline control: 2.0 mL saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18 years of age and older

          -  If female of childbearing potential, subject is non-pregnant, non-nursing, and agrees
             to use highly effective methods of contraception for a minimum of 24 months
             post-treatment

          -  Signed informed consent and country-appropriate privacy forms indicating subject is
             willing to undergo treatment and willing to be available for each examination
             scheduled over the study duration

          -  Have documented diagnosis of moderate radiographic degeneration of an intervertebral
             disc from L1 to S1, with a disc suspected of causing CLBP Chronic low back pain
             associated with moderate radiographic degeneration at a lumbar disc is defined as the
             following (subject must meet all of the listed conditions):

               1. Chronic low back pain for at least 6 months

               2. Have failed 6 months of conservative back pain care. (Conservative treatment
                  regimens may include any or all of the following: initial rest, medications
                  [e.g., anti-inflammatory, analgesics, narcotics/opioids, muscle relaxants],
                  massage, acupuncture, chiropractic manipulations, activity modification,
                  home-directed lumbar exercise program, and non-invasive pain control treatments
                  or procedures)

               3. Have at a minimum undergone supervised physical therapy, such as daily walking
                  routines, therapeutic exercises, and back education programs specifically for the
                  treatment of low back pain AND taken a pain medication for back pain (e.g. NSAID
                  and/or opioid medication).

               4. Change from normal disc morphology of the index disc as defined by radiographic
                  evaluation by the core imaging evaluation provider. Radiographs must show all of
                  the following:

          -  A modified Pfirrmann score of 3, 4, 5 or 6 on MRI at the index disc

          -  Modic Grade II changes or less on MRI at the index disc

          -  With or without contained disc protrusion at the index disc on MRI

             e. Low back pain of at least 40mm and not more than 90mm of 100mm on low back pain VAS
             (average pain over 24 hours)

             f. Leg pain ≤20mm in both legs on a 100mm VAS scale

             g. ODI score of at least 30 and no more than 90 on a 100 point scale.

        Exclusion Criteria:

          -  Female subjects who are pregnant or nursing, or women planning to become pregnant in
             the first 24 months post-treatment

          -  Extreme obesity, as defined by NIH Clinical Guidelines Body Mass Index (BMI &gt; 40)

          -  Have undergone a surgical procedure (e.g. discectomy, intradiscal electrothermal
             therapy, intradiscal radiofrequency, artificial disc replacement, interbody fusion) on
             the disc at the index or adjacent level

          -  Osteoporosis, as defined by dual-energy X-ray absorptiometry (DEXA) scan. A DEXA
             T-score of ≤ -2.5 will exclude the subject.

          -  Any lumbar intradiscal injection, including steroids, into the index or adjacent discs
             prior to treatment injection, with the exception of the following injections performed
             at least 2 weeks prior to study treatment:

               1. Contrast medium (discography or other diagnostic injection)

               2. NSAIDs

               3. Nerve-blocking anesthetics (e.g., lidocaine, bupivacaine)

               4. Antibiotics

               5. Saline

          -  Have undergone a procedure affecting the structure/biomechanics of the index disc
             level (e.g., posterolateral fusion)

          -  Active malignancy or tumor as source of symptoms or history of malignancy within the 5
             years prior to enrolment on study

          -  Have been a recipient of prior allogeneic stem cell/progenitor cell therapy for any
             indication or autologous stem cell/progenitor cell therapy or other biological
             intervention to repair the index intervertebral disc

          -  An average baseline morphine equivalent dose (MED) of &gt;75mg/day as determined by
             e-diary entries during the screening period

          -  Taking systemic immunosuppresants

          -  A medical condition, serious intercurrent illness, or extenuating circumstance that
             would preclude participation in the study or potentially decrease survival or
             interfere with ambulation or rehabilitation.

          -  Subjects involved in spinal litigation, including workman's compensation, unless
             litigation is complete

          -  Are transient or has a severe alcohol or substance abuse problem

          -  Clinically significant nerve pain (e.g., chronic radiculopathy or neuropathy)

          -  Clinically significant sacroiliac joint pain

          -  Compressive pathology due to stenosis or disc protrusion on MRI with associated
             clinical symptoms defined as leg pain VAS&gt;20mm out of 100mm or neurologic deficit on
             neurologic exam

          -  Disc extrusion with a maximum dimension greater or equal to twice the posterior height
             of the disc, or disc sequestration in the lumbar spine on MRI as determined by
             radiographic core lab

          -  Modified Pfirrmann score of 7 or 8 at any lumbar level (L1-S1) on MRI evaluation as
             determined by radiographic core lab

          -  Symptomatic involvement of more than one lumbar disc

          -  Symptomatic central vertebral canal stenosis as defined by neurogenic claudication

          -  Spondylolisthesis or retrolisthesis Grade 2 and above or Spondylolysis at the index or
             adjacent level(s)

          -  Lumbar spondylitis or other undifferentiated spondyloarthropathy affecting the index
             disc

          -  Spinal deformity defined as lumbar scoliosis with a Cobb angle of the lumbar spine
             greater than 15 degrees

          -  Any fracture of the spine at the index or adjacent levels that has not healed, or
             clinically compromised vertebral bodies at the index level due to current or past
             trauma

          -  Facet pain at the index level or adjacent segments as determined by a diagnostic
             medial branch block (a facet block injection is not acceptable for making this
             determination) to rule out facet joint involvement.

          -  Full thickness annular tears in the index level as determined by free flowing contrast
             media through the annulus fibrosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Brown</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Valley Pain Consultants</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pain Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Research Group</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284-2604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020-4124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Orthopaedics Surgical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newport Beach Headache and Pain</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Regenerative Medicine and Clinical Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Spine Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Pain Specialists</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Spine Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Pain Alliance</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Pain Management</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Back Pain Specialists, LLC</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research Specialists</name>
      <address>
        <city>Fernandina Beach</city>
        <state>Florida</state>
        <zip>32034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shrock Orthopedic Research, LLC</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Orthopedics Institute</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Orthopaedics &amp; Spine Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Institute for Clinical Research, LLC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Injury Care Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Pain Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otrimed Clinical Research</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Specialists of Louisiana</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAPS Applied Research Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Pain Care Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ainsworth Institute of Pain Management</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Regional Health</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Neurosurgery and Spine Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>On Site Clinical Solutions, LLC</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research/ Carolinas Pain Institute</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DOC Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigations, LLC</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic and Spine Specialists</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RI Hospital-Comprehensive Spine Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Research, Inc.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Back Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Team Texas</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Spine Care</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the SMART Clinic</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia iSpine Physicians, PC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Center</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lumbar Back Pain</keyword>
  <keyword>Low back pain</keyword>
  <keyword>Back pain</keyword>
  <keyword>Degenerative Disc Disease</keyword>
  <keyword>Injection of Degenerated Lumbar Disc</keyword>
  <keyword>Intervertebral Disc Degeneration</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Pain</keyword>
  <keyword>Spinal Diseases</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Adult Stem Cells</keyword>
  <keyword>Allogeneic Mesenchymal Precursor cells (MPCs)</keyword>
  <keyword>Mesoblast</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Pharmaceutical Solutions</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Protective Agents</keyword>
  <keyword>rexlemestrocel-L</keyword>
  <keyword>Viscosupplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

